6 Sept 2026
Integrated in vitro and in silico evaluations of novel benzanilide derivatives as anticancer agentsPublisher siteFuture Medicinal Chemistry, Angiogenesis and VEGF in Cancer
UniversitiesWalid E. Elgammal
Active, last published 2026
In synthesis and biological activity
Walid E.
Elgammal
Scholar“Research focused on Synthesis and biological activity and adjacent fields.”
Al-Azhar University
Claim Your Profile17
H-index
785
Citations
Walid has not officially claimed their profile. If you are Walid, claim it free.
Claim Your Profile
Pioneer
LOCKED
Pathfinder
LOCKED
Scholar
EARNED
Innovator
LOCKED
Inventor
LOCKED
Catalyst
LOCKED
Expert
UPGRADE
01 · About the work
What I study
alid E. Elgammal is a researcher working on Synthesis and biological activity. A fuller summary will appear once they update their profile.
02 · Reach
Publication output and reach
Walid's work has been cited 785 times across 3 active years. Bars show publications per year; the line shows cumulative citation totals across publications first appearing in each year.
03 · Research focus
Topics
Synthesis and biological activity×33Angiogenesis and VEGF in Cancer×21Click Chemistry and Applications×10Cancer, Hypoxia, and Metabolism×9Nanocomposite Films for Food Packaging×9
04 · Where I am
Affiliations
Affiliation on published researchAl-Azhar UniversityDrawn from the institution listed on this researcher’s published work.
Research themes (UN SDGs)
05 · Selected work
Recent publications
30 works26 Aug 2026
Rational design of a bis-acetanilide hydrazone–thiourea hybrid as a potent VEGFR-2 inhibitor: in silico and in vitro evaluationsPublisher siteChemical Papers, Angiogenesis and VEGF in Cancer
29 May 2026Open access
Theoretical–experimental study of new synthesized hydrazine–hydrazone benzenesulfonamide inhibitors for carbon steel in a 1.0 M hcl: DFT, QSARPublisher siteScientific Reports, Corrosion Behavior and Inhibition
28 May 2026
Development of a Novel Benzanilide Derivative Targeting VEGFR-2: Computational Modeling and <i>In Vitro</i> Anticancer ValidationPublisher siteJournal of Computational Biophysics and Chemistry, Angiogenesis and VEGF in Cancer
25 May 2026
New N-(isoxazol-3-yl)-4-(1,3,4-thiadiazol-3(2H)-yl)benzenesulfonamide derivatives as potent Aurora kinases inhibitors: Design, synthesis and anti-proliferative activityPublisher siteBioorganic Chemistry, Microtubule and mitosis dynamics
1 May 2026
Structure‐Guided Design and Mechanistic Elucidation of New Chromene Derivatives as Selective Vascular Endothelial Growth Factor Receptor‐2 Inhibitors With Potent Anticancer ActivityPublisher siteDrug Development Research, Angiogenesis and VEGF in Cancer
13 Apr 2026Open access
Structure-guided optimization of N-sulfonylpiperidines toward potent multi-target anticancer agentsPublisher siteScientific Reports, Histone Deacetylase Inhibitors Research
1 Mar 2026
Thiadiazole‐Derived <scp>VEGFR</scp> ‐2 Inhibitors: From Design to Anticancer EvaluationPublisher siteChemical Biology & Drug Design, Angiogenesis and VEGF in Cancer
Expert Academic Profiles go further
Citation trend analytics, exportable publication records, and direct enquiry routing from industry and funders.
Are you Walid?
Claim it to verify your details, connect with industry partners, and explore Fractional Domain Expert opportunities through MARATTO™.
African researchers are full of potential that too often goes unrecognised. Your MARATTO™ profile gives your work the commercial pathway it deserves.
Claim Your Profile
Free to claim · takes a minute to verify it’s you